Baidu
map

内分泌科指南

订阅

MedSci主页 / 所有栏目 / 内分泌科指南

2018 AACE/ACE共识声明：2型糖尿病综合管理方案

2018-01-10 美国临床内分泌医师学会 Endocr Pract.Vol 24 No. 1 January 2018.

2型糖尿病综合管理

2018年1月，美国临床内分泌医师学会(AACE)更新发布了2型糖尿病综合管理方案共识声明。2018版2型糖尿病综合管理方案更新了生活方式治疗部分。

中文标题：

2018 AACE/ACE共识声明：2型糖尿病综合管理方案

英文标题：

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2018 EXECUTIVE SUMMARY

发布机构：

美国临床内分泌医师学会

发布日期：

2018-01-10

简要介绍：

2018年1月，美国临床内分泌医师学会(AACE)更新发布了2型糖尿病综合管理方案共识声明。2018版2型糖尿病综合管理方案更新了生活方式治疗部分。

 

拓展指南：与2型糖尿病相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 AACE/ACE共识声明：2型糖尿病综合管理方案)] GetToolGuiderByIdResponse(projectId=1, id=3de7e1c0015a390c, title=2018 AACE/ACE共识声明：2型糖尿病综合管理方案, enTitle=CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2018 EXECUTIVE SUMMARY, guiderFrom=Endocr Pract.Vol 24 No. 1 January 2018., authorId=null, author=, summary=2018年1月，美国临床内分泌医师学会(AACE)更新发布了2型糖尿病综合管理方案共识声明。2018版2型糖尿病综合管理方案更新了生活方式治疗部分。 , cover=, journalId=null, articlesId=null, associationId=79, associationName=美国临床内分泌医师学会, associationIntro=美国临床内分泌医师协会是一家致力于内分泌学，糖尿病和代谢方面研究的专业医师协会，该机构努力提高其成员的能力以提供最高质量的患者护理。, copyright=0, guiderPublishedTime=Wed Jan 10 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<P>2018年1月，美国临床内分泌医师学会(AACE)更新发布了2型糖尿病综合管理方案共识声明。2018版2型糖尿病综合管理方案更新了生活方式治疗部分。 </P> <P> </P>拓展指南：<strong>与<font color=red>2型糖尿病</font>相关指南：</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=c66081c00153606a" title="2017 KDA立场声明：胰高血糖素样肽-1受体激动剂治疗2型糖尿病" target=_blank>2017 KDA立场声明：胰高血糖素样肽-1受体激动剂治疗2型糖尿病</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=9bbef1c00153309f" title="2017 SIGN国家临床指南：2型糖尿病患者血糖控制的药物管理（154）" target=_blank>2017 SIGN国家临床指南：2型糖尿病患者血糖控制的药物管理（154）</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=b5a591c0015251ed" title="中国2型糖尿病合并血脂异常防治专家共识（2017年修订版）" target=_blank>中国2型糖尿病合并血脂异常防治专家共识（2017年修订版）</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=975a71c001522852" title="关于2型糖尿病合并慢性肾脏病患者应用胰岛素治疗的专家指导建议" target=_blank>关于2型糖尿病合并慢性肾脏病患者应用胰岛素治疗的专家指导建议</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=5d0d21c00151830e" title="2017年ACP《2型糖尿病口服药物治疗临床实践指南》解读" target=_blank>2017年ACP《2型糖尿病口服药物治疗临床实践指南》解读</a></li> 更多信息请点击：<a href="//m.capotfarm.com/guideline/list.do?q=2%E5%9E%8B%E7%B3%96%E5%B0%BF%E7%97%85" target=_blank>有关2型糖尿病更多指南</a></ul>, tagList=[TagDto(tagId=2052, tagName=2型糖尿病), TagDto(tagId=50289, tagName=综合管理)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=1, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8600, appHits=540, showAppHits=0, pcHits=5533, showPcHits=3170, likes=156, shares=19, comments=4, approvalStatus=1, publishedTime=Mon Jan 15 10:57:20 CST 2018, publishedTimeString=2018-01-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Jan 15 10:57:20 CST 2018, updatedBy=null, updatedName=null, updatedTime=Thu Jan 04 22:42:10 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 AACE/ACE共识声明：2型糖尿病综合管理方案)])
2018 AACE/ACE共识声明：2型糖尿病综合管理方案
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=320811, encodeId=5798320811c7, content=求中文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fef11736881, createdName=丹歌, createdTime=Sat Jun 02 10:45:43 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280108, encodeId=374828010844, content=学习了.谢谢., beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Jan 19 19:49:16 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278782, encodeId=659d2e878257, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Mon Jan 15 17:57:42 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278724, encodeId=4c442e8724a8, content=学习了.谢谢., beContent=null, objectType=guider, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Mon Jan 15 13:12:11 CST 2018, time=2018-01-15, status=1, ipAttribution=)]
    2018-06-02 丹歌

    求中文版

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=320811, encodeId=5798320811c7, content=求中文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fef11736881, createdName=丹歌, createdTime=Sat Jun 02 10:45:43 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280108, encodeId=374828010844, content=学习了.谢谢., beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Jan 19 19:49:16 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278782, encodeId=659d2e878257, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Mon Jan 15 17:57:42 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278724, encodeId=4c442e8724a8, content=学习了.谢谢., beContent=null, objectType=guider, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Mon Jan 15 13:12:11 CST 2018, time=2018-01-15, status=1, ipAttribution=)]
    2018-01-19 虈亣靌

    学习了.谢谢.

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=320811, encodeId=5798320811c7, content=求中文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fef11736881, createdName=丹歌, createdTime=Sat Jun 02 10:45:43 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280108, encodeId=374828010844, content=学习了.谢谢., beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Jan 19 19:49:16 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278782, encodeId=659d2e878257, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Mon Jan 15 17:57:42 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278724, encodeId=4c442e8724a8, content=学习了.谢谢., beContent=null, objectType=guider, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Mon Jan 15 13:12:11 CST 2018, time=2018-01-15, status=1, ipAttribution=)]
    2018-01-15 1e0e5a1fm42(暂无匿称)

    henhao

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=320811, encodeId=5798320811c7, content=求中文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fef11736881, createdName=丹歌, createdTime=Sat Jun 02 10:45:43 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280108, encodeId=374828010844, content=学习了.谢谢., beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Fri Jan 19 19:49:16 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278782, encodeId=659d2e878257, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Mon Jan 15 17:57:42 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278724, encodeId=4c442e8724a8, content=学习了.谢谢., beContent=null, objectType=guider, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Mon Jan 15 13:12:11 CST 2018, time=2018-01-15, status=1, ipAttribution=)]
    2018-01-15 惠映实验室

    学习了.谢谢.

    0

相关指南

2017 KDA立场声明：胰高血糖素样肽-1受体激动剂治疗2型糖尿病

韩国糖尿病协会(KDA,Korean Diabetes Association) · 2017-12-15

2017 SIGN国家临床指南：2型糖尿病患者血糖控制的药物管理（154）

苏格兰校际指南网络(SIGN,Scottish Intercollegiate Guidelines Network) · 2017-11-30

中国2型糖尿病合并血脂异常防治专家共识（2017年修订版）

中华医学会内分泌学分会(CSE,Chinese Society of Endocrinology) · 2017-11-28

关于2型糖尿病合并慢性肾脏病患者应用胰岛素治疗的专家指导建议

中国内分泌相关专家小组（统称） · 2017-10-30

2017年ACP《2型糖尿病口服药物治疗临床实践指南》解读

暂未更新 · 2017-11-30

2017 VA/DoD临床实践指南：2型糖尿病的管理

退伍军人卫生署和美国国防部(VA/DoD,Veterans Health Administration and the US Department of Defense) · 2017-10-24

Baidu
map
Baidu
map
Baidu
map